Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder
- PMID: 15059031
- DOI: 10.2165/00129785-200404020-00003
Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder
Abstract
Attention deficit-hyperactivity disorder (ADHD) is a very common and heterogeneous childhood-onset psychiatric disorder, affecting between 3% and 5% of school age children worldwide. Although the neurobiology of ADHD is not completely understood, imbalances in both dopaminergic and noradrenergic systems have been implicated in the origin and persistence of core symptoms, which include inattention, hyperactivity, and impulsivity. The role of a genetic component in its etiology is strongly supported by genetic studies, and several investigations have suggested that the dopamine transporter gene (DAT1; SLC6A3 locus) may be a small-effect susceptibility gene for ADHD. Stimulant medication has a well-documented efficacy in reducing ADHD symptoms. Methylphenidate, the most prescribed stimulant, seems to act mainly by inhibiting the dopamine transporter protein and dopamine reuptake. In fact, its effect is probably related to an increase in extracellular levels of dopamine, especially in brain regions enriched in this protein (i.e. striatum). It is also important to note that dopamine transporter densities seem to be particularly elevated in the brain of ADHD patients, decreasing after treatment with methylphenidate. Altogether, these observations suggest that the dopamine transporter does play a major role in ADHD. Among the several polymorphisms already described in the SLC6A3 locus, a 40 bp variable number of tandem repeats (VNTR) polymorphism has been extensively investigated in association studies with ADHD. Although there are some negative results, the findings from these reports indicate the allele with ten copies of the 40 bp sequence (10-repeat allele) as the risk allele for ADHD. Some investigations have suggested that this polymorphism can be implicated in dopamine transporter gene expression in vitro and dopamine transporter density in vivo, even though it is located in a non-coding region of the SLC6A3 locus. Despite all these data, few studies have addressed the relationship between genetic markers (specifically the VNTR) at the SLC6A3 locus and response to methylphenidate in ADHD patients. A significant effect of the 40 bp VNTR on response to methylphenidate has been detected in most of these reports. However, the findings are inconsistent regarding both the allele (or genotype) involved and the direction of this influence (better or worse response). Thus, further investigations are required to determine if genetic variation due to the VNTR in the dopamine transporter gene is able to predict different levels of clinical response and palatability to methylphenidate in patients with ADHD, and how this information would be useful in clinical practice.
Similar articles
-
Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD.Pharmacogenomics J. 2014 Feb;14(1):77-84. doi: 10.1038/tpj.2013.9. Epub 2013 Apr 16. Pharmacogenomics J. 2014. PMID: 23588108
-
Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder.Biol Psychiatry. 2001 Feb 15;49(4):333-9. doi: 10.1016/s0006-3223(00)01053-2. Biol Psychiatry. 2001. PMID: 11239904
-
Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies.Mol Psychiatry. 2016 Jul;21(7):872-84. doi: 10.1038/mp.2016.74. Epub 2016 May 24. Mol Psychiatry. 2016. PMID: 27217152 Free PMC article. Review.
-
Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD.Am J Med Genet B Neuropsychiatr Genet. 2003 Aug 15;121B(1):50-4. doi: 10.1002/ajmg.b.20071. Am J Med Genet B Neuropsychiatr Genet. 2003. PMID: 12898575
-
Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics.Pharmacogenomics. 2005 Apr;6(3):225-34. doi: 10.1517/14622416.6.3.225. Pharmacogenomics. 2005. PMID: 16013954 Review.
Cited by
-
Study of changes in rs2283265 polymorphisms in dopamine receptor D2 and rs27072 in dopamine transporter gene (SLC6A3) in patients with attention-deficit hyperactivity disorder.Iran J Child Neurol. 2022 Summer;16(3):121-132. doi: 10.22037/ijcn.v15i4.25340. Epub 2022 Jul 16. Iran J Child Neurol. 2022. PMID: 36204439 Free PMC article.
-
Promising Developments in the Use of Induced Pluripotent Stem Cells in Research of ADHD.Curr Top Behav Neurosci. 2022;57:483-501. doi: 10.1007/7854_2022_346. Curr Top Behav Neurosci. 2022. PMID: 35543866
-
Characterization of a Dopamine Transporter and Its Splice Variant Reveals Novel Features of Dopaminergic Regulation in the Honey Bee.Front Physiol. 2019 Nov 1;10:1375. doi: 10.3389/fphys.2019.01375. eCollection 2019. Front Physiol. 2019. PMID: 31736791 Free PMC article.
-
Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment.Neuropsychiatr Dis Treat. 2016 May 5;112:1085-101. doi: 10.2147/NDT.S94158. eCollection 2016. Neuropsychiatr Dis Treat. 2016. PMID: 27226715 Free PMC article.
-
The effects of age, gender, hopelessness, and exposure to violence on sleep disorder symptoms and daytime sleepiness among adolescents in impoverished neighborhoods.J Youth Adolesc. 2015 Feb;44(2):518-42. doi: 10.1007/s10964-014-0160-5. Epub 2014 Jul 29. J Youth Adolesc. 2015. PMID: 25070645
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical